🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

4,838 results for “SP” Clear

  1. Doxorubicin Hydrochloride

    Children's Hospital of Fudan University

    Childhood Renal Cell Carcinoma

    phase 2 small molecule completed

    1 trial

  2. Doxorubicin liposome

    The First People's Hospital of Lianyungang

    Breast Cancer

    phase 2 small molecule active

    1 trial

  3. Doxycycline

    Hospital Authority, Hong Kong

    Tuberculosis, Meningeal

    phase 2 small molecule active

    1 trial

  4. Dragon Boat Training

    The First People's Hospital of Lianyungang

    Breast Cancer

    phase 2 other active

    1 trial

  5. Drug-coated balloon angioplasty

    The First People's Hospital of Lianyungang

    Vertebral Artery Stenosis

    phase 2 other active

    1 trial

  6. Drug: Pembrolizumab

    Hospital Authority, Hong Kong

    Clear-cell Metastatic Renal Cell Carcinoma

    phase 2 other active

    1 trial

  7. Dupilumab

    Hospital Authority, Hong Kong

    Nephrotic Syndrome in Children

    phase 2 mab active

    1 trial

  8. Durability of protection after single immunisation with genetically attenuated Plasmodium falciparum ∆mei2 (GA2) sporozoites – a follow-up, controlled human malaria rechallenge study

    Disc Medicine

    Falciparum malaria

    phase 2 other active

    1 trial

  9. EBV-TCR-T (YT-E001) cells

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Nasopharyngeal Carcinoma

    phase 2 mab active

    1 trial

  10. EBV-specific T cells (EBV-CTLs)

    Evidence Based Cataract Study Group

    EBV-induced Lymphomas

    phase 2 mab completed

    1 trial

  11. EBVALLO

    Pierre Fabre Medicament

    EBV+ primary imunodeficiency lymphoproliferative disease (LPD), EBV+ post-transplant LPD where standard first line therapy (rituximab or chemotherapy) is inappropriate, including CD20-negative disease, EBV+ sarcomas, including leiomyosarcoma, or smooth muscle tumors, EBV+ associated post-transplant LPD involving the central nervous system (EBV+ CNS PTLD)

    phase 2 small molecule active

    1 trial

  12. EDP-938

    ENANTA PHARMACEUTICALS INC

    Respiratory Syncytial Virus Infections

    phase 2 small molecule terminated

    1 trial

  13. EDP-938

    ENANTA PHARMACEUTICALS INC

    Respiratory Syncytial Virus (RSV)

    phase 2 small molecule completed

    2 trials

  14. EDP-938

    ENANTA PHARMACEUTICALS INC

    Respiratory Syncytial Virus

    phase 2 small molecule completed

    1 trial

  15. EDP-938, EDP-938 Placebo tablets

    ENANTA PHARMACEUTICALS INC

    Respiratory syncytial virus (RSV)

    phase 2 small molecule active

    1 trial

  16. EGFR Antibody

    The First People's Hospital of Lianyungang

    Nasopharyngeal Cancinoma (NPC)

    phase 2 small molecule active

    1 trial

  17. EGFR-TK Inhibitor

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Nonsmall Cell Lung Cancer

    phase 2 small molecule active

    1 trial

  18. ENCORAFENIB , CETUXIMAB

    The George Institute

    Patients with BRAF V600E-mutant metastatic colorectal cancer (mCRC) who had received and responded to a BRAF inhibitor-based treatment.

    phase 2 small molecule active

    1 trial

  19. EPINEPHRINE , Briquilimab

    Jasper Therapeutics

    Chronic Inducible Urticaria

    phase 2 small molecule active

    1 trial

  20. EPINEPHRINE NASAL SPRAY, Placebo Nasal Spray, EPINEPHRINE NASAL SPRAY

    Ars Pharmaceuticals Irl Limited

    Chronic Spontaneous Urticaria (CSU)

    phase 2 small molecule active

    1 trial

  21. ER004

    Pierre Fabre Medicament

    X-linked hypohidrotic ectodermal dysplasia (XLHED)

    phase 2 small molecule active

    1 trial

  22. ETC-1002

    Esperion Therapeutics

    Dyslipidemia

    phase 2 small molecule completed

    1 trial

  23. ETC-1002

    Esperion Therapeutics

    Hyperlipidemia

    phase 2 small molecule completed

    2 trials

  24. ETOPOSIDE, YTB323, CYTARABINE, CYCLOPHOSPHAMIDE MONOHYDRATE, BENDAMUSTINE HYDROCHLORIDE, FLUDARABINE PHOSPHATE, IBRUTINIB, TOCILIZUMAB

    Novartis Pharmaceuticals

    High-Risk large B-Cell lymphoma, Chronic lymphocytic leukemia/Small lymphocytic lymphoma, Diffuse large B-Cell lymphoma, Acute lymphoblastic leukemia

    phase 2 small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources